CH Biomedical was Invited to Speak at 2022 EUMS-ISMCS Conference

May 24-27, 2022 International Society for Mechanical Circulatory Society (ISMCS) and European Mechanical Circulatory Society (EUMS) Joint Scientific Conference was successfully held in Hanover, Germany. Dr. Frank Lin, PhD, CTO of CH Biomedical, and Mr. Karl Nelson, Vice President of Clinical Operations were invited to attend the conference.

2022.05.31 1006

NMPA Announcement | CH-VAD®Approved for Marketing in China: An Implantable Left Ventricular Assist Device of CH Biomedical, Opening a New Era of Heart Failure Treatment

On November 25th 2021, the implantable CH-VAD® left ventricular assist system (CH-VAD® LVAS) of CH Biomedical was approved by the National Medical Products Administration (NMPA) for marketing (Registration  No.: GXZZ 20213120987). CH-VAD LVAS was developed independently by CH Biomedical, it is the first Left Ventricular Assist Device (LVAD) with complete independent intellectual property rights approved by NMPA in China, and the first full magnetic levitation LVAD approved by NMPA.

2021.12.08 1911